Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

about

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).The functional verification of EGFR-CAR T-cells targeted to hypopharyngeal squamous cell carcinoma

P2860

Q55709201-0B5F8438-BF62-41BE-8A86-B96E851074C0 Q58558222-4FF736EB-5B88-4E9B-B131-2599B89053BE

P2860

Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

Item

http://www.wikidata.org/entity/Q48255324

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Building upon the success of C ...... for hematologic malignancies.

@en

Building upon the success of C ...... for hematologic malignancies.

@nl

type

Item

label

Building upon the success of C ...... for hematologic malignancies.

@en

Building upon the success of C ...... for hematologic malignancies.

@nl

prefLabel

Building upon the success of C ...... for hematologic malignancies.

@en

Building upon the success of C ...... for hematologic malignancies.

@nl

P1476

Building upon the success of C ...... s for hematologic malignancies

@en

P2093

Anastasios Karadimitris

http://www.w3.org/2001/XMLSchema#string

Antonia Rotolo

http://www.w3.org/2001/XMLSchema#string

Marco Ruella

http://www.w3.org/2001/XMLSchema#string

P2860

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances

An update of current treatments for adult acute myeloid leukemia

CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma

Developing strategies in the immunotherapy of leukemias

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

P304

2040-2055

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1403024

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marco Ruella

Antonia Rotolo

Anastasios Karadimitris

P577

2017-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29165008

http://www.w3.org/2001/XMLSchema#string

P932

6814196

http://www.w3.org/2001/XMLSchema#string

Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

about

P2860

P2860

Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932